Psoriasis treatment has expanded dramatically over the past decade, and the growth shows no signs of stopping, as many prominent players such as Abbvie, Jannsen, Dermavant Sciences, UCB, Eli Lilly and Company, Boehringer Ingelheim, Pfizer, Arcutis Biotherapeutics, Amgen, Mylan, Clover Biopharmaceuticals, Sienna Biopharmaceuticals, Fresenius Kabi, Celltrion, Bristol Myers Squibb, LEO Pharma, Crescita Therapeutics, GlaxoSmithKline, Coherus BioSciences, Fujifilm Kyowa Kirin Biologics, Zydus Cadilla, Shanghai Henlius Biotech, Hetero Biopharma, CinnaGen, Biocad, Torrent Pharmaceuticals, Alvotech, Maruho Co., Ltd., Arcutis Biotherapeutics, Inc., Eli Lilly and Company, Can-Fite Biopharma, MetrioPharm, Provectus Pharmaceuticals, Sienna Biopharmaceuticals and many others are developing Psoriasis therapies.
Los Angeles, USA , March 02, 2021 (GLOBE NEWSWIRE) -- Psoriasis Pipeline Insight 2021 | Latest Advancements in Clinical Trials to Improve Treatment
Psoriasis treatment has expanded dramatically over the past decade, and the growth shows no signs of stopping, as many prominent players such as Abbvie, Jannsen, Dermavant Sciences, UCB, Eli Lilly and Company, Boehringer Ingelheim, Pfizer, Arcutis Biotherapeutics, Amgen, Mylan, Clover Biopharmaceuticals, Sienna Biopharmaceuticals, Fresenius Kabi, Celltrion, Bristol Myers Squibb, LEO Pharma, Crescita Therapeutics, GlaxoSmithKline, Coherus BioSciences, Fujifilm Kyowa Kirin Biologics, Zydus Cadilla, Shanghai Henlius Biotech, Hetero Biopharma, CinnaGen, Biocad, Torrent Pharmaceuticals, Alvotech, Maruho Co., Ltd., Arcutis Biotherapeutics, Inc., Eli Lilly and Company, Can-Fite Biopharma, MetrioPharm, Provectus Pharmaceuticals, Sienna Biopharmaceuticals and many others are developing Psoriasis therapies.
DelveInsight’s “Psoriasis Pipeline Insight'' report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Psoriasis pipeline landscapes. It comprises Psoriasis pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Psoriasis therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Psoriasis pipeline products.
Psoriasis Pipeline seems to be robust as more than 20 molecules are in the registration/pre-registration phase, around 15 molecules are in Phase III, around 40 molecules are in Phase II, around 35 molecules are in Phase I/II or Phase I and around 15 molecules are in Preclinical Phase.
The current Psoriasis pipeline features Biologics, Topical & Oral, and therapeutic candidates, which are being designed to be delivered with specially designed delivery vehicles. Most of the Psoriasis pipeline drugs are Biologics /Oral.
Biologics have given patients the possibility of complete psoriasis clearance and control of their psoriatic arthritis (PsA), which a major unmet need of Psoriasis treatment. Newer biologics offer unprecedented efficacy & also provide lengthy remissions.
The launch of various biologic therapies is expected in the next 3-5 years for the Psoriasis treatment.
Psoriasis is a chronic, immune-mediated inflammatory skin disease, which is characterized by the presence of papules and plaques occurring mainly on the elbows, knees, scalp, and lower back but is not restricted to these areas.
There is no cure for Psoriasis; however, there are multiple effective treatment options; topical therapy is the standard of care for treatment.
Prominent Players: Abbvie, Jannsen, Dermavant Sciences, UCB, Eli Lilly and Company, Boehringer Ingelheim, Pfizer, Arcutis Biotherapeutics, Amgen, Mylan, Clover Biopharmaceuticals, Sienna Biopharmaceuticals, Fresenius Kabi, Celltrion, Bristol Myers Squibb, LEO Pharma, Crescita Therapeutics, GlaxoSmithKline, Coherus BioSciences, Fujifilm Kyowa Kirin Biologics, Zydus Cadilla, Shanghai Henlius Biotech, Hetero Biopharma, CinnaGen, Biocad, Torrent Pharmaceuticals, Alvotech, Maruho Co., Ltd., Arcutis Biotherapeutics, Inc., Eli Lilly and Company, Can-Fite Biopharma, MetrioPharm, Provectus Pharmaceuticals, Sienna Biopharmaceuticals and many others.
Key Drugs Profiles: 80+ Products
Phases:
Psoriasis Therapies Late-stage (Phase III)
Psoriasis Therapies (Phase II)
Psoriasis Therapies (Phase I)
Psoriasis Therapies Pre-clinical stage and Discovery candidates
Discontinued and Inactive candidates
Therapies:
Cell Therapy
Monoclonal Antibodies
Protein
Small Molecule
Route of Administration:
Intramuscular
Intravenous
Oral
Parental
Topical
Transdermal
Mechanism of Action:
Immunosuppressants
Tumour necrosis factor alpha inhibitors
Aryl hydrocarbon receptor agonists
IL17F protein inhibitors
Interleukin-23 subunit p19 inhibitors
Interleukin 12 inhibitors
Interleukin 23 inhibitors
Key Questions regarding Current Psoriasis Treatment Landscape and Emerging Therapies Answered in the Pipeline Report
What are the current options for Psoriasis treatment?
How many companies are developing therapies for the treatment of Psoriasis?
How many Psoriasis emerging therapies are in the early-stage, mid-stage, and late stages of development for the treatment of Psoriasis?
What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact the Psoriasis market?
Which are the dormant and discontinued products and the reasons for the same?
What is the unmet need for current therapies for the treatment of Psoriasis?
What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing Psoriasis therapies?
What are the key designations that have been granted for the emerging therapies for Psoriasis?
How many patents are granted and pending for the emerging therapies for the treatment of Psoriasis?
Table of Contents
1
Psoriasis Report Introduction
2
Psoriasis Overview
3
Psoriasis Current Treatment Patterns
4
Psoriasis Analytical Perspective
5
Psoriasis Pipeline Therapeutic Assessment
6
Psoriasis Late Stage Products (Phase III)
7
Psoriasis Mid Stage Products (Phase II)
8
Psoriasis Pre-clinical Products and Discovery Stage Products
DelveInsight's Psoriasis - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.
DelveInsight's Psoriasis - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Psoriasis in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
DelveInsight's Chronic Plaque Psoriasis - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.
DelveInsight's Mild To Moderate Plaque Psoriasis - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.
DelveInsight's Moderate Psoriasis - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.
DelveInsight's Phototherapies for Psoriasis - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.
DelveInsight's Plaque Psoriasis - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.
DelveInsight's Psoriasis Vulgaris - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.
